School of Pharmacy, Jinzhou Medical University, Jinzhou, P R China.
Department of Pharmacology, Jinzhou Medical University, Jinzhou, P R China.
Drug Deliv. 2020 Dec;27(1):745-755. doi: 10.1080/10717544.2020.1762262.
It is reported that quercetin (Que) can prevent tau pathology and induce neuroprotection by improving cognitive and functional symptoms in the treatment of Alzheimer's disease (AD). However, its clinical application has been limited due to its poor brain targeting and bioavailability. Exosomes are considered as cargo carriers for intercellular communication and especially serve as a natural and important drug brain delivery platform for achieving better treatment of central neurological diseases. Here, we developed plasma exosomes (Exo) loaded with Que (Exo-Que) to improve the drug bioavailability, enhance the brain targeting of Que and potently ameliorate cognitive dysfunction in okadaic acid (OA)-induced AD mice. Our results showed that Exo-Que improved brain targeting of Que as well as significantly enhanced bioavailability of Que. Furthermore, compared with free Que, Exo-Que better relieved the symptoms of AD by inhibiting cyclin-dependent kinase 5 (CDK5)-mediated phosphorylation of Tau and reducing formation of insoluble neurofibrillary tangles (NFTs), suggesting its therapeutic potential for better treatment of AD.
据报道,槲皮素(Que)可以通过改善阿尔茨海默病(AD)的认知和功能症状来预防 Tau 病理学并诱导神经保护。然而,由于其脑靶向性和生物利用度差,其临床应用受到限制。外泌体被认为是细胞间通讯的载体,特别是作为一种天然的、重要的药物脑递药平台,可实现中枢神经系统疾病的更好治疗。在这里,我们开发了载有 Que 的血浆外泌体(Exo-Que),以提高药物的生物利用度,增强 Que 的脑靶向性,并有效改善冈田酸(OA)诱导的 AD 小鼠的认知功能障碍。我们的结果表明,Exo-Que 改善了 Que 的脑靶向性,并显著提高了 Que 的生物利用度。此外,与游离 Que 相比,Exo-Que 通过抑制周期蛋白依赖性激酶 5(CDK5)介导的 Tau 磷酸化和减少不溶性神经原纤维缠结(NFTs)的形成,更好地缓解了 AD 的症状,表明其在更好地治疗 AD 方面具有治疗潜力。